Inside the Clinic: Treating AYA ALL - Episode 4

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

, ,

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Clinical Scenario: A 23-Year-Old Male with AYA ALL
    EP. 2: AYA ALL: Overview and Risk Stratification
    EP. 3: AYA ALL: Pediatric and Adult Inspired Regimens
    Now Viewing
    EP. 4: AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
    EP. 5: Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions
    EP. 6: ALL AYA: Coordination of Care
    EP. 7: Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL
    EP. 8: CALBG 10403 in AYA ALL
    EP. 9: The Potential of Modified Treatment Regimens in AYA ALL
    EP. 10: The Future of AYA ALL

    Video content above is prompted by the following questions:

    • Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.
      • How does for asparaginase erwinia chrysanthemi work?
      • What are your thoughts on the key efficacy outcomes?
    x